PolyPid Ltd. (PYPD)
| Market Cap | 15.53M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -47.16M |
| Shares Out | 19.66M |
| EPS (ttm) | -2.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 92,549 |
| Open | 0.820 |
| Previous Close | 0.810 |
| Day's Range | 0.780 - 0.840 |
| 52-Week Range | 0.650 - 6.900 |
| Beta | 1.26 |
| Analysts | Buy |
| Price Target | 3.44 (+335.44%) |
| Earnings Date | Feb 8, 2023 |
About PYPD
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for PYPD stock is "Buy." The 12-month stock price forecast is $3.44, which is an increase of 335.44% from the latest price.
News
PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023
PETACH TIKVA, Israel, Jan. 31, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...
PolyPid Provides Positive Regulatory Update for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
• Regulatory Pathway for a Potential NDA Submission Clarified Following Recent Interactions with the FDA
PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery
D-PLEX 100 Achieved in Phase 2 Trial Significant Reduction in SSIs in Patients with Multiple Preoperative Risk Factors Versus Standard of Care
PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
Meeting Scheduled for January 2023
PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification
PETACH TIKVA, Israel, Dec. 09, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced it...
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association
D-PLEX₁₀₀ Infection Prevention Efficacy in Patients with Increased Risk for Surgical Wound Infections Including Multi-Drug Resistant Organisms (MDROs) will be Presented During a Podium Presentation D-...
PolyPid Provides Corporate Update and Reports Third Quarter 2022 Financial Results
PETACH TIKVA, Israel, Nov. 09, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (PolyPid or the Company), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corpo...
PolyPid to Report Third Quarter 2022 Financial Results and Operational Highlights on November 9, 2022
PETACH TIKVA, Israel, Oct. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...
PolyPid Announces Cost Reduction Plan
Reduction of Approximately 20% in Organization Headcount
PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery
Centralized Procedure Allows for Submission of a Single Marketing Application to the European Medicines Agency that, if Approved, Would Allow D-PLEX 100 to be Marketed in All EU Member States
PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery
Intends to discuss the Clinical Outcomes and Next Steps for D-PLEX 100 for the Prevention of SSIs in Abdominal Surgery with the FDA and the EU Regulatory Authorities in Q1 2023
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the European Society for Coloproctology Scientific Conference
Efficacy Data of D-PLEX 100 in the Prevention of Post-Abdominal Surgery Incisional Infection will be Presented During a Podium Presentation
PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery
SHIELD I Study did not Achieve its Primary Endpoint of Reduction in Surgical Site Infections and Mortality
Wall Street Analysts Think PolyPid Ltd. (PYPD) Could Surge 206%: Read This Before Placing a Bet
The mean of analysts' price targets for PolyPid Ltd. (PYPD) points to a 205.6% upside in the stock.
PolyPid Announces Presentation at the 2022 Military Health System Research Symposium
Efficacy Data of D-PLEX 100 in reduction of Surgical Site Infection in Surgical Trauma Injuries will be Presented During a Podium Presentation
All You Need to Know About PolyPid Ltd. (PYPD) Rating Upgrade to Buy
PolyPid Ltd. (PYPD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Wall Street Analysts Believe PolyPid Ltd. (PYPD) Could Rally 223%: Here's is How to Trade
The mean of analysts' price targets for PolyPid Ltd. (PYPD) points to a 222.9% upside in the stock.
PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results
PETACH TIKVA, Israel, Aug. 10, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a c...
PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX₁₀₀ in Europe
PolyPid to potentially receive over $110 million in upfront and milestone payments as well as royalties on net sales
PolyPid to Report Second Quarter 2022 Financial Results and Operational Highlights on August 10, 2022
PETACH TIKVA, Israel, July 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the Midwest Surgical Association 2022 Annual Meeting
Efficacy Data of D-PLEX 100 in the Prevention of Post-Abdominal Surgery Incisional Infection in High-Risk Patients will be Presented During a Podium Presentation
PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO
Company Previously Announced Planned CEO Transition Following Retirement of Amir Weisberg Company Previously Announced Planned CEO Transition Following Retirement of Amir Weisberg
PolyPid Hosting Key Opinion Leader Webinar on Managing the Cost of Surgical Site Infections
PETACH TIKVA, Israel, June 15, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...
PolyPid Announces Presentation of D-PLEX₁₀₀ Phase 2 Clinical Data at ASM Microbe 2022
Phase 2 clinical data on the efficacy of D-PLEX 100 in surgical site infection prevention in elective colorectal surgery will be presented during a poster presentation
PolyPid to Present at the JMP Securities 2022 Life Sciences Conference
PETACH TIKVA, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced t...